Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute mylogenous leukemia cell line

Oncology Letters

Volumn 1, Issue 3, 2010, Pages 473-479

  Girgis, Erian ^a,b   Mahoney, John ^a,b   Darling Reed, Selina ^a,b   Soliman, Magdi ^a,b  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b Tallahassee Memorial Hospital   (United States)

Author keywords

Acute myeloid leukemia; Arsenic trioxide; Thalidomide

Indexed keywords

ALDESLEUKEN; ARSENIC TRIOXIDE; RECOMBINANT INTERLEUKIN 2; THALIDOMIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOTHESIS; LEUKEMIA CELL LINE;

EID: 77955726433     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000083     Document Type: Article

References (48)

1. Godwin JE and Smith SE: Acute myeloid leukemia in the older patient. Crit Rev Oncol Hematol 48: S17-S26, 2003.
2. Harousseuau JL: Acute myeloid leukemia in the elderly. Blood Rev 12: 145-153, 1988.
3. Cortes JE and Kantarjian HM: Acute lymphocytic leukemia: A comprehensive review with emphasis on biology and therapy. Cancer 76: 2393-2417, 1995.
4. Estey EH, Kantarjian H and Keating MJ: Therapy for acute myeloid leukemia. In: Hematology: Basic Principles and Practice. 2nd edition Hoffman R, Benz E Jr, Shattil S, Cohen H and Silberstein L (eds). Churchill Livingstone, New York, pp1014-1028, 1994.
5. Thomas DA, Kantarjian Hand Smith TL: Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86: 1216-1230, 1999.
6. Beran M, Estey E and O'Brien S: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17: 2819-2830, 1999.
7. Estey EH, Kantarjian HM and O'Brien S: High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther 1: 21-28, 1995.
8. Thomas D: Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders. Semin Oncol 37 (Suppl 3): 26-34, 2000.
9. Lu C and Hassan HT: Human stem cell factor-antibody (anti-SCF) enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukemia cells. Leuk Res 30: 296-302, 2006.
10. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H and Garcia-Manero G: Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res 29: 739-748, 2005.
11. Koeffler HP, Billing R, Lusis AJ, Sparkes R and Golde DW: An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood 56: 265-273, 1980.
12. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS and Boise LH: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98: 805-813, 2001.
13. Block G and Levine M: Vitamin C: a new look. Ann Intern Med 114: 909-910, 1991.
14. Sakagami H and Satoh K: Modulating factors of radical intensity and cytotoxic activity of ascorbate [review]. Anticancer Res 17: 3513-3520, 1997.
15. Dai J, Weinberg RS, Waxman S and Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93: 268-277, 1999.
16. Kruse FF, Joussen AM, Rohrschneider K, Becker MD and Volcker HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236: 461-466 1998.
17. Corral LG, Haslett PAJ, Muller GW, et al: Differential cytokine modulation and T-cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163: 380-386, 1999.
18. Haslett PAJ, Corral LG, Albert M and Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187: 1885-1892, 1998.
19. Geitz H, Handt S and Zwingenberger K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31: 213-221, 1996.
20. Du GJ, Lin HH, Xu QT and Wang MW: Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol 43: 112-119, 2005.
21. Heslop HE, Rooney CM and Brenner MK: Gene-marking and hemopoietic stem cell transplantation. Blood Rev 4: 220-224, 1995.
22. Barret AJ: Mechanisms of the graft-versus-leukemia reactivity. Bone Marrow Transplant 1: 61-68, 1997.
23. Ball ED, Mills LE, Cornwell GG Jr, Davis BH, Coughlin CT and Howell AL: Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow. Blood 75: 1199-1206, 1990.
24. Sznol M and Parkinson DR: Interleukin-2 in therapy of hematologic malignancies. Blood 83: 2020-2222, 1994.
25. Uckun FM, Kersey JH, Vallera DA, Ledbetter JA, Weisdorf D and Myers DE: Autologous bone marrow transplantation in high risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 76: 1723-1733, 1990.
26. Kalland T, Belfrage H, Bhiladvala P and Hedlund G: Analysis of the murine lymphokine-activated killer (LAK) phenomenon: dissection of effectors and progenitors into NK- and T-like cells. J Immunol 38: 3640-3645, 1987.
27. Ochoa AC, Gromo G, Alter BJ, Sondel PM and Bach FH: Long-term growth of lymphokine-activated killer (LAK)-cells: role of anti CD-3, beta-IL1, interferon-gamma and -beta. J Immunol 138: 2728-2733, 1987.
28. Peace DJ, Kern DE, Schultz KR, Greenberg PD and Cheever MA: IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T-cell-like large granular lymphocytes. J Immunol 140: 3679-3685, 1988.
29. Naume B and Espevik T: Effects of IL-7 and IL-12 on highly enriched CD56+ natural killer cells: a comparative study. J Immunol 147: 2208-2214, 1991.
30. Stewart-Akers AM, Cairns JS, Tweardy DJ and McCarthy SA: Effect of granulocyte macrophage-colony stimulating factor on lymphokine-activated killer cell induction. Blood 81: 2672-2678, 1993.
31. Rojas R, Roman J, Herrera C, Alvarez MA, Ramirez R and Torres A: BALB/C mice injected with LSTRA leukemic cell line are cured by in vivo treatment with IL-2 + GM-CSF. Leuk Res 27: 351-357, 2003.
32. Herrera C, Garcia-Perez MJ, Ramirez R, Martin C, Alvarez MA and Martinez F: Lymphokine-activated killer (LAK)-cell generation from peripheral blood stem cells by in vitro incubation with low dose interleukin-2 plus granulocyte macrophage-colony stimulating factor. Bone Marrow Transplant 19: 545-551, 1997.
33. Evens AM, Tallman MS and Gartenhaus RB: The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 28: 891-900, 2004.
34. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F and Berger R: NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086, 1991.
35. Chen GQ, Shi XG, Tang W, et al: Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): I. Arsenic trioxide exerts dose-dependent dual effects on APL cells. Blood 89: 3345-3353, 1997.
36. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW and Lee CC: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60: 3065-3071, 2000.
37. Perkins C, Kim CN, Fang G and Bhalla KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95: 1014-1022, 2000.
38. Schor NF, Rudin CM, Hartman AR, Thompson CB, Tyurina YY and Kagan VE: Cell line dependence of Bcl-2-induced alteration of glutathione handling. Oncogene 19: 472-476, 2000.
39. Davison K, Mann KK, Waxman S and Miller WH: JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103: 3496-3502, 2004.
40. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A and Davison K. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90: 124-133, 1998.
41. Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A and Yamato K: Arsenic trioxide-induced apoptosis and differentiation in retinoic acid resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 14: 431-438, 2000.
42. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH and Brouet JC: Arsenic trioxide and Melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59: 1041-1048, 1999.
43. Liu Q, Hilsenbeck S and Gazitt Y: Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101: 4078-4087, 2003.
44. Deaglio S, Canella D, Baj G, Arnulfo A, Waxman S and Malavasi F: Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide on myeloma cells. Leuk Res. 25: 227-235, 2001.
45. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL and Warrell Jr RP: Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96: 1525-1530, 2000.
46. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y and Gordon LI: Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 8: 666-672, 2002.
47. Kitamura K, Minami Y, Yamamoto K, et al: Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 14: 1743-1750, 2000.
48. Gupta S, Yel L, Kim D, Kim C, Chiplunkar S and Gollapudi S: Arsenic trioxide induces apoptosis in peripheral blood T lymphocytes subsets by inducing oxidative stress: a role of Bcl-2. Mol Cancer Ther 2: 711-719, 2003.